Towards Healthcare

Neurodiagnostics Market Addressing Patient Access, Affordability, and Health Equity Issues in Diagnostics

Based on our market research, the neurodiagnostics market was valued at USD 19.05 billion in 2025 and is projected to grow from USD 20.68 billion in 2026 to USD 43.27 billion by 2035, expanding at a CAGR of 8.55% during 2026–2035

Last Updated : 11 March 2026 Category: Diagnostics Insight Code: 6745 Format: PDF / PPT / Excel
Revenue, 2025
USD 19.05 Billion
Forecast, 2035
USD 43.27 Billion
CAGR, 2026-2035
8.55%
Report Coverage
Global

The global neurodiagnostics market size was estimated at USD 19.05 billion in 2025 and is predicted to increase from USD 20.68 billion in 2026 to approximately USD 43.27 billion by 2035, expanding at a CAGR of 8.55% from 2026 to 2035.

Neurodiagnostics Market Size is USD 20.68 Billion in 2026.

The neurodiagnostics market is growing, as increasing its applications in various disorders, including epilepsy and seizure monitoring, neuromuscular disorders, sleep disorders, intraoperative neuromonitoring, functional brain mapping, neonatal care, and various diagnostic modalities.

Key Takeaways

  • The neurodiagnostics market will likely exceed USD 20.68 billion by 2026.
  • Valuation is projected to hit USD 43.27 billion by 2035.
  • Estimated to grow at a CAGR of 8.55% starting from 2026 to 2035.
  • North America dominated the neurodiagnostics market in 2025.
  • Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
  • By technology, the neuroimaging technologies segment dominated the market in 2025.
  • By technology, the in vitro diagnostics segment is expected to fastest growing in the market during the forecast period.
  • By end use, the hospitals and clinics segment dominated in 2025.
  • By end use, the imaging centers segment is expected to grow fastest in the market during the forecast period.

Market Overview: What is Neurodiagnostics?

The neurodiagnostics market is growing because of neurodiagnostics to support the diagnosis of disorders affecting the spinal cord, brain, and peripheral nervous system, like epilepsy. Applications involve localizing pathology, such as traumatic brain injury and focal epilepsy, using source imaging and different processes of analysis. It supports physicians in identifying and diagnosing brain and nerve-related conditions. Intraoperative neurophysiology enables real-time monitoring of brain and nerve function during neurosurgical events.

How is AI governing the Neurodiagnostics Market?

Integration of AI-driven technology in neurodiagnostics drives market growth, as AI-based technology has become significantly integrated in medical care, specifically in the diagnosis of neurological disorders. This development has allowed neurologists and physicians to diagnose conditions more rapidly and effectively. The incorporation of computational neuroscience with AI-driven diagnostics offers a potential pathway for early intervention and targeted neurotherapeutic approaches. Advanced AI-based tools are renovating neurodiagnostics in data analysis, interpretation, detection, and identification of disorders, and understanding the challenges in the human brain.

  • Blood-Based Biomarkers: Blood-based biomarkers provide a significant advance in the healthcare evaluation of neurodegenerative diseases. Blood-driven biomarkers for neurodegenerative diseases are quickly evaluated in studies, and they have the potential to enter clinical use soon in various clinical settings.
  • Advancement in Neuroinformatics: Neuroinformatics, the integration of neuroscience and AI-based processes, is advancing technologies such as brain-driven interfaces, AI-based cognitive improvements, and personalized neuromodulation for managing neurological disorders.
  • Point-of-care (POC) in Neurodiagnostic: Point-of-care electroencephalography (POC-EEG) systems allow rapid brain activity assessment via reduced electrode arrays strategically placed at consumer or manufacturer-driven locations.

Key Indicators and Highlights

Table Scope
Market Size in 2026 USD 20.68 Billion
Projected Market Size in 2035 USD 43.27 Billion
CAGR (2026 - 2035) 8.55%
Leading Region North America by 36%
Historical Data 2020 - 2023
Base Year 2025
Forecast Period 2026 - 2035
Measurable Values USD Millions/Units/Volume
Market Segmentation By Technology, By End Use, By Region
Top Key Players Canon Medical Systems Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., Thermo Fisher Scientific, Inc, FUJIFILM Corporation, Natus Medical Incorporated

Segmentation Analysis

By Technology Insights

Which Technology Led the Neurodiagnostics Market in 2025?

In 2025, the neuroimaging technologies segment held the dominant market in 2025, due to neuroimaging playing a significant role in non-invasively detecting brain activity, supporting unravelling how different regions contribute to cognitive and behavioural processes such as memory, perception, attention, language, decision-making, and emotional regulation. This transformation has created the way for improved monitoring, diagnosis, and treatment of neurological services. Neuroimaging technologies were originally intended for laboratory purposes to fulfill particular and unconventional measurement needs.

In-vitro Diagnostics

Whereas the in vitro diagnostics segment is the fastest-growing in the neurodiagnostics market during the forecast period, as it allows early detection, precise diagnosis, targeted treatment, and continuous monitoring, it also reduces medical care expenses and drives health care innovation. IVDs provide a significant solution, enabling providers to deliver operative, efficient, and personalized care. In vitro diagnostics identify diseases or other conditions, and are used to monitor a patient's overall health to support cure, manage, or prevent diseases. In-vitro diagnostics are used in precision medicine to detect patients who are likely to benefit from particular treatments or therapies.

By End Use Insights

Why did the Hospitals and Clinics Segment Dominate the Market in 2025?

The hospitals and clinics segment is dominant in the neurodiagnostics market in 2025, as neurodiagnostic technologies significantly work in hospitals and clinics using sophisticated services to capture data that supports physicians to detect and diagnose oncology and nerve-related conditions such as epilepsy, multiple sclerosis, and strokes.  Early detection of neurological disorders plays a significant role in enhancing patient outcomes, improving quality of life, and reducing long-term complexities.

Imaging Centers

Whereas the imaging centers segment is the fastest-growing in the market, as imaging centers are services intended to perform health imaging solutions to produce high-definition images of tissues, bones, organs, arteries, blood vessels, and the nervous system. Imaging centers provide various services such as MRI, CT Scans, X-Rays, Mammography, DEXA Bone Scans, PET Scans, Electromyography, and Ultrasounds. Imaging centers are smaller allows for more tailored care. Imaging centers enhance the diagnostic experience by providing reliable scheduling, lower wait times, and helpful environments.

Regional Insights

Neurodiagnostics Market Shares for North America, Europe, Asia Pacific, Latin America and Middle East and Africa, 2025 (%).

Regions Share 2025 (%)
North America 36%
Europe 30%
APAC 23%
Latin America 7%
Middle East and Africa 4%

How did North America dominate the Market in 2025?

In 2025, North America dominated the neurodiagnostics market by 36% due to robust healthcare infrastructure, portable health initiatives, and online health records. The focus is increase to shift toward creating a more effective, patient-driven healthcare technology. AI-based EEG analysis improves neurological monitoring, mental health valuation, and BCI applications, making these devices a more valuable tool for continuous and personalized medical care. The increasing rates of disease burden (DALYs) are found in this region, which drives the growth of the market.

U.S. Market Trends

In the U.S., a growing number of chronic diseases, an estimated 129 million people in the US have at least 1 major chronic disease. The United States leads the world in transformational technologies. The increasing number of scientific discoveries, the skillfull personal to develop progressive technology. Rising government attention focused on innovation, supply chains, and the workforce, which increases the demand for neurodiagnostics services.

Prevalence of Alzheimer's and other dementias in the United States

An estimated 7.2 million Americans age 65 and older are living with Alzheimer's dementia in 2025.

Prevalence of Alzheimer’s in 2025

Age Range Cases (million)
65-74 years 1.9
75-84 years 2.8
85+ 2.5

Asia Pacific: Increasing Investment Efficiency

Asia Pacific is expected to see rapid growth in the neurodiagnostics market, driven by the region's medical care sector, which has massive strength for growth, and organizations that drive modernization. Increasing investment efficiency was higher when switching regulatory investment predisposition in the aspect of medical infrastructure construction toward less developed regions. Demand for digital medical care in the Asia Pacific continues to grow because of the economy and care. This region is leading revolutionary progress in neuroscience, using its expanded demographics, various disease loads, and fast-expanding research technology, which drives the growth of the market.

India Market Trends

Rising advancement in healthcare technology and development of neuroepidemiology in India over the last few decades have been documented, highlighting the historical keystone. The increasing aging population and significant lifestyle transformation have made neurological diseases a key public health challenge, which has increased demand for neurodiagnostics services. India's healthcare sector is increasing in leaps and bounds, supported by regulatory spending and the private industry's innovative spirit.

Europe: Increasing Cases of Neurological Disorders

Europe is growing significantly in the neurodiagnostics market, as the increasing prevalence of neurological disorders like Alzheimer's disease, Parkinson's disease, and epilepsy is driving demand for advanced diagnostic services. Alzheimer's disease is the most common type of dementia and contributes to 60–70% of cases in this region. European medical care plan intended to improve neurological health, involving prevention, early diagnosis, research, and novel research to allow efficient therapies, care, and social support, which is significant to mitigate the growing impact of neurodegenerative disorders.

Germany Market Trends

Germany’s advanced healthcare technology, such as an AI-based research ecosystem, is powered by centres of excellence, strategic investment, and programmes helping small and medium-sized enterprises (SMEs) and academia. Germany is the home of healthcare robotics, like the da Vinci system, and well-developed diagnostic imaging technology. Germany has an advanced medical care system, particularly with respect to infrastructure, hospital beds, and skilled staff.

Supply Chain Analysis

R&D:

  • Research and Development (R&D) in neurodiagnostics includes a multidisciplinary, multi-stage technology goal to create, enhance, and validate devices to identify neurological conditions earlier and more exactly.
  • Key Players: Abbott Laboratories and Canon

Manufacturing Processes:

  • Manufacturing processes in neurodiagnostics involve a wide range of high-accuracy processes designed to create sensitive sensors, imaging tools, and implantable tools to assess the nervous system.
  • Key Players: Philips Healthcare and Natus Medical

Patient Services:

  • Patient services for neurodiagnostics involve diagnostic testing procedures, imaging services, procedural and specialized services, patient care, and safety protocols
  • Key Players: Siemens Healthineers and GE Healthcare

Latest Updates of Key Players in the Neurodiagnostics Market

Neurodiagnostics Market Companies are Canon Medical Systems Corporation, Siemens Healthineers AG, Koninklijke Philips N.V., Thermo Fisher Scientific, Inc

Company Headquarters Latest Update
Canon Medical Systems Corporation United States In November 2025, Canon Medical Systems USA, Inc. recently received FDA 510 clearance for its Aplio i-series diagnostic ultrasound systems with Software Version 9.0.
Siemens Healthineers AG Germany Siemens Healthineers is increasing innovation by developing new blood-based biomarker assays for both healthcare use and neuroscience studies.
Koninklijke Philips N.V. Netherlands In November 2025, Royal Philips, a worldwide leader in health technology, announced an increasing collaboration with Cortechs.ai, a pioneer in quantitative neuroimaging services.
Thermo Fisher Scientific, Inc. United States Thermo Fisher Scientific is massively focused on increasing its AI-based medicine development, high-throughput imaging, and advanced diagnostics, specifically via the acquisition of Clario and the Olink Explore Platform.
FUJIFILM Corporation United States In October 2025, FUJIFILM Corporation announced plans to open the NURA health screening center, focusing on cancer screening, in four major cities across ASEAN: Ho Chi Minh City (Vietnam), Bangkok (Thailand), Manila (Philippines), and Kuala Lumpur (Malaysia).
Natus Medical Incorporated United States In December 2025, Natus Medical Incorporated announced the electrographic status epilepticus diagnosis ability of its BrainWatch point-of-care EEG services, featuring integrated Persyst analysis software, which has received 510(k) authorization from the U.S. Food and Drug Administration.

SWOT Analysis

Strengths

  • Advancements in neurodiagnostic technology have made it possible for physicians to understand challenging brain and nervous system disorders with massive accuracy.
  • Evolving a strong understanding of neuroimaging and other neurodiagnostic processes significantly enhances a rehabilitation professional’s capability to evaluate and adapt treatment plans.

Weaknesses

  • Neurodiagnostic technologists often face complexities like managing patients with different levels of cooperation and dealing with challenging or vital diagnostic requests.
  • Neurodiagnostic EEG or MRI needs patients to remain still, which can be difficult for toddlers, the elderly, or confused patients.

Opportunities

  • Advanced imaging technology like functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET) scans is offering unprecedented insights into the workings of the human brain.
  • Neurofeedback and biofeedback are evolving regions in neurodiagnostic research. Neurofeedback includes training individuals to regulate their own brain waves, although biofeedback includes teaching people to control other physiological functions like heart rate and muscle tension.

Threats

  • Lack of awareness related to the profession, to the requirement for continuous learning and adaptation to technological development.
  • Imaging of the children's brain is complex because of rapid structural changes in advancing brains, high water content in unmyelinated tissue.

Recent Developments in the Neurodiagnostics Market

  • In November 2025, RapidAI, the inventor of deep clinical AI and worldwide leader in enterprise imaging, announced U.S. Food and Drug Administration (FDA) clearance of Aortic Management, part of the Rapid Aortic product, a comprehensive deep clinical AI service designed to transform the acute assessment and longitudinal management of aortic disease.
  • In September 2025, Natus Medical Incorporated, the largest worldwide pure-play neurodiagnostics organization, announced it had acquired the remaining minority shares in Holberg EEG, the ground-breaking developer of the world's first artificial intelligence (AI) model capable of automatic and inclusive clinical EEG interpretation with precision on par with leading medical specialists.
  • In April 2025, a global leader in neurodiagnostic, neuromonitoring, and sleep solutions, Cadwell Industries, Inc., announced its strategic investment in Seer Medical, a Melbourne, Australia-driven organization specializing in home-based epilepsy diagnostics. The investment was made in collaboration with investors Breakthrough Victoria and TrialCap.

Segments Covered in the Report

By Technology

  • Neuroimaging Technologies
  • Computed Tomography (CT)
    • Magnetic Resonance Imaging (MRI)
    • Nuclear Medicine Imaging (PET, SPECT)
    • Near infrared spectroscopic imaging (NIRS)
    • Electro-encephalography (EEG)
    • Magneto-encephalography (MEG)
    • Voxel-based morphometry (VBM)
  • In Vitro Diagnostics
  • Neuroinformatics

By End Use

  • Hospitals and Clinics
  • Diagnostic Laboratories
  • Imaging Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada 
    • Mexico 
    • Rest of North America
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe 
    • Western Europe 
      • Germany 
      • Italy
      • France
      • Netherlands
      • Spain
      • Portugal 
      • Belgium
      • Ireland
      • UK 
      • Iceland 
      • Switzerland
      • Poland
      • Rest of Western Europe
    • Eastern Europe 
      • Austria
      • Russia & Belarus 
      • Türkiye
      • Albania 
      • Rest of Eastern Europe 
  • Asia Pacific
    • China 
    • Taiwan
    • India 
    • Japan 
    • Australia and New Zealand
    • ASEAN Countries (Singapore, Malaysia)
    • South Korea 
    • Rest of APAC 
  • MEA 
    • GCC Countries
      • Saudi Arabia 
      • United Arab Emirates (UAE)
      • Qatar 
      • Kuwait 
      • Oman 
      • Bahrain 
    • South Africa
    • Egypt 
    • Rest of MEA

FAQ's

Finding : The neurodiagnostics market in 2026 is valued at USD 20.68 billion and is projected to climb to USD 43.27 billion by 2035, with a CAGR of 8.55% over the forecast period.

Finding : North America is dominant in the neurodiagnostics market by 36% due to high disease prevalence and the presence of advanced infrastructure & R&D.

Finding : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.

Tags

Meet the Team

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and strategy.

Learn more about Shivani Zoting

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar

Related Reports

Neurodiagnostics Market
Updated Date: 11 March 2026   |   Report Code: 6745
WhatsApp